Kauf mal einen Franzosen !!
| eröffnet am: | 09.03.10 21:40 von: | Biggemann |
| neuester Beitrag: | 25.04.21 02:01 von: | Petralrcya |
| Anzahl Beiträge: | 148 | |
| Leser gesamt: | 50672 | |
| davon Heute: | 32 | |
bewertet mit 6 Sternen |
||
|
|
||
21.11.14 17:54
#129
Bob der Bob
der nächste heiße kandidat ist..
für mich synta
https://de.finance.yahoo.com/q?s=SNTA
https://de.finance.yahoo.com/q?s=SNTA
24.11.14 09:35
#131
erte
@Bob der Bob
Sieht so aus das wir beiden da den Richtigen Riecher gehabt haben :-)
02.12.14 10:21
#132
erte
Siehe:
AEterna Zentaris Aktie [WKN: A1J5XC / ISIN: CA0079753038] Denke die Aktie wird noch stark ansteigen!!
09.01.15 15:07
#134
iwanooze
RT fra !!explosion
http://www.boerse-frankfurt.de/de/aktien/...dr+eo+13+adr+US2683111072
09.01.15 16:02
#135
zamo9
.... jetzt noch in der USA die FDA-Zulassung
dann schiebt es hier richtig;-)))))
12.01.15 13:29
#136
iwanooze
edap premarket nasdaq
http://www.nasdaq.com/extended-trading/premarket-mostactive.aspx
15.01.15 12:35
#138
max06
Hallo
Wann wird das Jahresergebnis von 2014 bekanntgegeben? Bzw. die Zahlen zum 4 Quartal?
13.02.15 20:45
#140
scalper_scally
Edap steigt und steigt,
und kein Interesse hier im Board?
Sehr aufschlussreich!
Sehr aufschlussreich!
13.02.15 21:35
#141
elch01
Deshalb geht sie wohl ab heute..
Interventional Radiology: Guerbet partners HECAM project
12.02.2015 18:02
The HECAM(1) project is a €41 million research and development competitiveness project, financed to the tune of €18.2 million as part of the future investments program(2). Its ambition is to develop detection, diagnosis and treatment tools for hepatocellular carcinoma (HCC), in other words primary liver cancer.
Originally an idea of Claire Corot (Guerbet’s Research & Innovation and Business Development Licensing Director and member of the board of directors of Medicen), the HCC multi-technological approach project was structured by GE Healthcare. Piloted by GE Healthcare, HECAM comprises Guerbet, seven SMEs(3) and three academic partners(4). They provide and develop first-rate scientific and technical competencies within the project.
The benefit of a collaborative approach for a disease with major health consequences such as HCC is huge. And France has excellent academic, structured research, particularly in the field of medical imaging, paving the way for the emergence of innovative solutions.
Click here to read the press release (only in french).
(1) HEpatocellular CArcinoma Multi-technological.
(2) The program is piloted by the French General Investment Commission (CGI) and operated by Bpifrance. Bpifrance, a subsidiary of the Caisse des Dépôts et de l’État, provides loans, guarantees and capital to companies, from their startup to flotation on the stock market.
(3) BioPredictive, CarThera and IntegraGen (Greater Paris Region), BioSIMS Technologies (Upper Normandy), Intrasense (Languedoc-Roussillon), EDAP TMS France and Fluoptics (Rhône-Alpes).
(4) Gustave Roussy, Europe’s leading cancer treatment center, the Paris Public Hospitals Group (with four hospitals: Beaujon, Jean Verdier, Henri Mondor and Paul Brousse) and the French Healthcare and Medical Research Institute (five INSERM units). The consortium is also supported by the Montpellier Regional University Hospital.
http://www.guerbet.com/our-group/news/2015/news/.../intervention.html
12.02.2015 18:02
The HECAM(1) project is a €41 million research and development competitiveness project, financed to the tune of €18.2 million as part of the future investments program(2). Its ambition is to develop detection, diagnosis and treatment tools for hepatocellular carcinoma (HCC), in other words primary liver cancer.
Originally an idea of Claire Corot (Guerbet’s Research & Innovation and Business Development Licensing Director and member of the board of directors of Medicen), the HCC multi-technological approach project was structured by GE Healthcare. Piloted by GE Healthcare, HECAM comprises Guerbet, seven SMEs(3) and three academic partners(4). They provide and develop first-rate scientific and technical competencies within the project.
The benefit of a collaborative approach for a disease with major health consequences such as HCC is huge. And France has excellent academic, structured research, particularly in the field of medical imaging, paving the way for the emergence of innovative solutions.
Click here to read the press release (only in french).
(1) HEpatocellular CArcinoma Multi-technological.
(2) The program is piloted by the French General Investment Commission (CGI) and operated by Bpifrance. Bpifrance, a subsidiary of the Caisse des Dépôts et de l’État, provides loans, guarantees and capital to companies, from their startup to flotation on the stock market.
(3) BioPredictive, CarThera and IntegraGen (Greater Paris Region), BioSIMS Technologies (Upper Normandy), Intrasense (Languedoc-Roussillon), EDAP TMS France and Fluoptics (Rhône-Alpes).
(4) Gustave Roussy, Europe’s leading cancer treatment center, the Paris Public Hospitals Group (with four hospitals: Beaujon, Jean Verdier, Henri Mondor and Paul Brousse) and the French Healthcare and Medical Research Institute (five INSERM units). The consortium is also supported by the Montpellier Regional University Hospital.
http://www.guerbet.com/our-group/news/2015/news/.../intervention.html
26.03.15 19:37
#143
max06
Tut sich hier noch was vor den Zahlen?
Bei den letzten Quartalszahlen ging es im Vorfeld schon nach oben.
02.04.15 11:24
#145
elch01
Full-year 2014 Financial Results
Eigentlich gute Zahlen bis auf die Kosten für die US Zulassung
Rekordumsatz im Jahr 2014 von 26,8 Mio. EUR (35,4 Mio. USD); 11% Wachstum gegenüber dem Vorjahr;
Gesamtjahr HIFU Umsatz stieg 70% gegenüber 2013;
Starke Cash-Position von 12,1 Mio. EUR (14,7 Mio. USD) zum 31. Dezember 2014;
Filing Direkt De-novo-Petition für Ablatherm HIFU pro FDA Diskussionen.
http://www.nasdaq.com/press-release/...ar-2014-results-20150401-01011
Rekordumsatz im Jahr 2014 von 26,8 Mio. EUR (35,4 Mio. USD); 11% Wachstum gegenüber dem Vorjahr;
Gesamtjahr HIFU Umsatz stieg 70% gegenüber 2013;
Starke Cash-Position von 12,1 Mio. EUR (14,7 Mio. USD) zum 31. Dezember 2014;
Filing Direkt De-novo-Petition für Ablatherm HIFU pro FDA Diskussionen.
http://www.nasdaq.com/press-release/...ar-2014-results-20150401-01011
21.01.16 16:53
#148
iwanooze
news!sehr gute!
http://www.nasdaq.com/press-release/...ocal-hifu-trial-20160119-00532
"The publication reports a 100% cancer specific survival at 5 years, a 94% rate of continence preservation and 80% rate of potency preservation."
"The publication reports a 100% cancer specific survival at 5 years, a 94% rate of continence preservation and 80% rate of potency preservation."